eFFECTOR Therapeutics to Participate in Upcoming Investor Conference [Yahoo! Finance]
eFFECTOR Therapeutics to Participate in Upcoming Investor Conference
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $24.00 price target on the stock.
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update